预约演示

USPTO issues notice of allowance for Windtree’s SERCA2A activators

2023-06-13

The activators might lead to the development of new therapies to treat heart failure. Credit: Ground Picture / Shutterstock.com.

The United States Patent and Trademark Office (USPTO) has issued a notiheart failurece for Windtree Therapeutics’ patent application covering a group of SERCA2A [a key protein in the cycle of heart failure] activators with a dual mechanism.

The company stated that the family of drug candidates of SERCA2a activators has similar mecWindtree Therapeuticsthose of istaroxime, a first-in-class duaSERCA2Anism therapy.heart failure

Recommended Reportsistaroxime

ReportsLOA and PTSR Model - ISB-1442 GlobalData

ReportsLOA and PTSR Model - (semaglutide + GIP analogue) GlobalData

View all

It might therefore lead to the development of new therapies to treat heart failure.

Dual mechanism SERCA2a activasemaglutidey inhibiting the Na+/K+ pump [an enzyme found in the membrane of all animal cells] and activating SERCA2a.

Windtree Therapeutics noted that these product candidates are intended to be both oral and IV therapies.

They might represent both an outpatient, oral therapy for chronic heaheart failured hospital discharge, and an inpatient therapy for the treatment of acute decompensated heart failure.

In April 2023, SERCA2al mechanism SERCA2a activator classNa+/K+ pumpndidates received a patent from the European Patent Office.SERCA2a

Windtree Therapeutics CEO and president Craig Fraser stated: “We are pleased to see the continued progress of our IP portfolio strategy for the dual mechanism SERCA2a activator family of drug candidates.

“The development strategy with these dual mechanism compouchronic heart failure‘fast follow-on’ drug candidates that can leverage the experience with acute decompensated heart failureial added feature of oral bioavailability for use as a treatment for chronic heart failure.

“This composition of matter patentSERCA2aents a key part of our plan for these assets and we look forwarEuropean Patent Officethe process from the USPTO.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构